Close

Press Releases

GigaGen Works to Develop Passive, Convalescent COVID-19 Therapy

GigaGen is developing a recombinant polyclonal antibody therapy (rCIG) to treat COVID-19. First uses are envisioned as treatments for severely ill coronavirus patients and individuals at high risk of contracting the disease, including healthcare professionals. โ€œWe are working toward an...

ideaPoint and WideTrial Launch Global Expanded Access Platform for COVID-19 Medicines

Anaquaโ€™s ideaPoint, a provider of medical affairs and innovation management solutions, announced a strategic partnership with clinical data company WideTrial to facilitate greater access to investigational medicines for physicians and patients dealing with COVID-19 worldwide. The projectโ€™s objective is to...

Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes

Abbott announced that the U.S. FDA has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in...

Bora strengthens business development team to support US growth

Bora Pharmaceuticals, a full-service contract development and manufacturing organization (CDMO) which specializes in immediate and modified release oral solids and packaging, has announced the appointment of Mr. Lonnie Barish, MBA as Vice President of Business Development and Marketing. Adding more...

Destroying DNA to Save the Genome – Study Offers New Insights into Sepsis and its Treatment

Sepsis is a life-threatening condition that kills millions annually; it is poorly understood and has no specific treatment. Now, researchers from Tata Memorial Centre, India, led by Prof. Dr Indraneel Mittra, have uncovered an important molecular mechanism underlying different...

C2 PHARMA Opens Government and Research Access to Safety Stock of DIGOXIN API for Use in Potential COVID-19 Combination Treatment

C2 PHARMA s.a.r.l. (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, is announcing that they will open access to safety stocks of the active pharmaceutical ingredient (API), Digoxin. In early March, the API was listed for...

FDA Provides Emergency Use Authorization to PerkinElmer for COVID-19 Testing

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that the U.S. FDA has provided Emergency Use Authorization (EUA) for the Companyโ€™s New Coronavirus RT-PCR test. Clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA)...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป